J&J builds case for earlier Tecvayli use in multiple myeloma
Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma.
Newsletters and Deep Dive digital magazine
Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma.
Novartis claims life sciences lie at the centre of a shift in geopolitics and policies in regions like Europe, Japan, and Canada are "self-defeating."
Novo Nordisk Foundation is pumping funding into a Copenhagen-based biotech incubator, seeking to address the challenge of funding access in Europe.
The FDA and EMA have come up with guiding principles that they say will underpin future guidance on the use of AI technologies in drug development.
Oxford BioMedica confirmed this morning that it has received an unsolicited approach from private equity group EQT about a possible takeover.
Editor's Picks
Newsletters and Deep Dive
digital magazine